A clinical trial evaluating PCT-3012 to reduce motor impairment in Parkinson's Disease patients
Latest Information Update: 15 Apr 2022
Price :
$35 *
At a glance
- Drugs PCT 3012 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 15 Apr 2022 New trial record